Antibody–Drug Conjugates Therapeutics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: 20 November 2025 | Viewed by 85
Special Issue Editors
Interests: monoclonal antibodies and other protein formulations; solid dosage forms; formulation of gene therapeutics; liposomal drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Interests: antibody–drug conjugates; glioblastoma multiforme; breast cancer; protein chemistry; drug delivery
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) are a promising class of cancer therapeutics. These conjugates consist of a monoclonal antibody linked to cytotoxic agents through chemical linkers. By leveraging the high specificity of monoclonal antibodies, ADCs enable precise drug delivery to target tissues, thereby enhancing the overall therapeutic index. The development of ADCs, however, is complex and faces numerous challenges, such as antigen selection, linker stability, drug resistance, and toxicity management. This Special Issue will focus on recent advancements in ADC design. Topics will include novel conjugation techniques, innovative payloads, improved linker technologies, and next-generation ADC platforms. Additionally, this Special Issue will explore mechanisms of action, clinical applications, and strategies to enhance therapeutic efficacy. Contributions on combination therapies, bispecific ADCs, and applications beyond oncology are also welcome. Both original research papers and comprehensive review articles are encouraged to contribute to the evolving landscape of ADC-based therapeutics.
We look forward to receiving your valuable contributions.
Prof. Dr. Amal Ali Elkordy
Dr. Summer Y. Y. Ha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody–drug conjugate
- drug delivery
- antibody
- payload
- linker
- protein conjugation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
